MG
LEXX icon

Mather Group’s Lexaria Bioscience LEXX Stock Holding History

Mather Group’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$363 – 1982
2024
Q2 		$363 Buy
+100
New +$300 ﹤0.01% 2094

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Mather Group's LEXX Position: Q3 2024 in Review

Mather Group sold out of Lexaria Bioscience (LEXX) in Q3 2024, closing a stake of 100 shares — an estimated $363 sold.

Mather Group first reported a position in LEXX in Q2 2024 and held it in 1 quarter. The position peaked at $363 in Q2 2024. 27 funds tracked by Wall St. Rank hold LEXX as of Q3 2024.

  • Mather Group reported no remaining Lexaria Bioscience position as of Q3 2024 after selling out during the quarter.
  • Mather Group sold 100 Lexaria Bioscience shares in Q3 2024, an estimated $363.
  • Mather Group first reported a position in Lexaria Bioscience in Q2 2024 and held it in 1 quarter.
  • Mather Group's Lexaria Bioscience position peaked at $363 in Q2 2024.
  • 27 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.